Loading…
Incyte Corporation is projected to rise to $115.41 by 2027, a +19% move from its current price of $97.34. INCY is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $96.22 | $97.35 | $98.49 | +0.01% |
| May 30 | $95.76 | $97.35 | $98.97 | +0.01% |
| May 31 | $95.42 | $97.36 | $99.35 | +0.02% |
| Jun 1 | $95.13 | $97.37 | $99.66 | +0.03% |
| Jun 2 | $94.87 | $97.37 | $99.94 | +0.04% |
| Jun 3 | $94.64 | $97.38 | $100.20 | +0.04% |
| Jun 4 | $94.43 | $97.39 | $100.44 | +0.05% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $94.43 | $97.39 | $100.44 | +0.05% |
| Week 2 | $93.28 | $97.44 | $101.78 | +0.10% |
| Week 3 | $92.42 | $97.49 | $102.83 | +0.15% |
| Week 4 | $91.70 | $97.53 | $103.74 | +0.20% |
| Week 5 | $91.08 | $97.58 | $104.55 | +0.25% |
| Week 6 | $90.53 | $97.63 | $105.29 | +0.30% |
| Week 7 | $90.03 | $97.68 | $105.98 | +0.35% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Incyte Corporation is a biopharmaceutical company that engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. Its portfolio includes JAKAFI for the treatment of myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/MINJUVI for diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease.
It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms; INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company’s clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; and Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa HS, and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreements with Novartis, Lilly, and Syndax.
The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
INCY trades at $97.16 per share and has a market capitalization of $19.41B. It ranks 602 in market capitalization. The stock’s near-term technicals show it trading above key moving averages, with SMA50 at $95.53 and SMA200 at $95.35, suggesting a modest near-term bullish tilt.
The 30-day price range is $89.54 to $105.43, with near-term support at $94.65 and resistance at $100.32. The year-by-year forecast outlines a path of upside, with a 2026 average of $97.16 and a long-run average of $780.53 by 2050, alongside a max forecast of $1,277.27 for 2050. These numbers imply meaningful upside over the horizon, though they are estimates and not guarantees.
A major floor 7.2% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.8% away) — a key level to hold.
The nearest ceiling, 3.1% above — a clean break opens room to run.
A major ceiling 12.0% above — clearing it would confirm fresh momentum.
Key INCY support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of INCY market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $97.22 | Buy | $97.12 | Buy |
| MA 10 | $96.86 | Buy | $97.13 | Buy |
| MA 20 | $97.51 | Sell | $97.10 | Buy |
| MA 50 | $95.71 | Buy | $96.96 | Buy |
| MA 100 | $98.62 | Sell | $96.69 | Buy |
| MA 200 | $95.54 | Buy | $92.93 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.35 | Neutral |
| Stoch RSI (14) | 46.34 | Neutral |
| CCI (20) | -10.08 | Neutral |
| Williams %R (14) | -58.09 | Info |
| MACD (12,26,9) | -0.12 | Sell |
| ROC (12) | -1.24 | Sell |
| Bollinger %B (20,2) | 0.47 | Neutral |
| Stochastic %K (14) | 41.91 | Neutral |
| TRIX (15) | 0.05 | Buy |
| Awesome (5,34) | 0.16 | Buy |
| Ultimate (7,14,28) | 67.66 | Neutral |
| Momentum (10) | -1.79 | Sell |
| Aroon Osc (25) | 44.00 | Buy |
| Hull MA (9) | 97.57 | Sell |
| ADX (14) | 7.32 | Neutral |
| ATR (14) | 0.98 | Info |
Sentiment remains BULLISH overall in the near term. RSI14 is 50, and the stock trades above the SMA50 of $95.53 and the SMA200 of $95.35, which can be consistent with continued strength.
The 30-day range is $89.54 to $105.43, with a defined support at $94.65 and resistance at $100.32. This provides a framework for near-term trading plans and potential pullbacks around the support level.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $90.30 | $97.34 | $132.17 | 0% | Neutral | |
| $94.28 | $115.41 | $147.87 | +19% | Neutral | |
| $98.81 | $123.16 | $161.93 | +27% | Bullish | |
| $109.62 | $138.70 | $186.16 | +42% | Bullish | |
| $114.55 | $146.87 | $200.60 | +51% | Bullish | |
| $137.96 | $179.02 | $248.33 | +84% | Bullish | |
| $161.26 | $211.60 | $297.65 | +117% | Bullish | |
| $164.25 | $217.78 | $310.27 | +124% | Bullish | |
| $181.56 | $243.11 | $350.46 | +150% | Bullish | |
| $189.92 | $256.70 | $374.14 | +164% | Bullish | |
| $283.78 | $399.99 | $610.75 | +311% | Bullish | |
| $502.01 | $758.74 | $1,241.51 | +679% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $90.30 | $97.34 | $113.98 | +0.00% |
| June 2026 | $83.15 | $97.00 | $115.35 | -0.35% |
| July 2026 | $83.50 | $97.97 | $117.61 | +1.01% |
| August 2026 | $85.65 | $100.94 | $122.06 | +3.03% |
| September 2026 | $85.81 | $101.50 | $123.46 | +0.56% |
| October 2026 | $85.30 | $101.25 | $123.81 | -0.26% |
| November 2026 | $87.46 | $104.12 | $127.93 | +2.84% |
| December 2026 | $89.70 | $107.10 | $132.17 | +2.86% |
Click any year to see its month-by-month INCY forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The INCY price prediction for 2026 points to an average of $97.34 (low $90.30, high $132.17) — a potential gain of 0% on today's $97.34. Price action looks broadly range-bound.
In 2027, INCY is projected to trade between $94.28 and $147.87, averaging $115.41 — a potential gain of +19% from today's $97.34. That is up +19% on the projected 2026 average. A consolidation phase looks the most probable path here.
Incyte Corporation's 2028 outlook centres on $123.16, within a $98.81 to $161.93 range. That is up +7% on the projected 2027 average. That marks a +27% change versus current levels. Momentum favours further upside here.
By 2029, INCY could reach as high as $186.16, with a base case around $138.70 and support toward $109.62 — roughly +42% from $97.34. Buyers look set to stay in control over this stretch.
Expect INCY to range from $114.55 to $200.60 through 2030. The $146.87 average target implies a +51% move from current prices. That is up +6% on the projected 2029 average. Momentum favours further upside here.
The INCY price prediction for 2031 points to an average of $179.02 (low $137.96, high $248.33) — a potential gain of +84% on today's $97.34. Buyers look set to stay in control over this stretch.
In 2032, INCY is projected to trade between $161.26 and $297.65, averaging $211.60 — a potential gain of +117% from today's $97.34. That is up +18% on the projected 2031 average. Momentum favours further upside here.
Incyte Corporation's 2033 outlook centres on $217.78, within a $164.25 to $310.27 range. That is up +3% on the projected 2032 average. That marks a +124% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, INCY could reach as high as $350.46, with a base case around $243.11 and support toward $181.56 — roughly +150% from $97.34. Momentum favours further upside here.
Expect INCY to range from $189.92 to $374.14 through 2035. The $256.70 average target implies a +164% move from current prices. That is up +6% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The INCY price prediction for 2040 points to an average of $399.99 (low $283.78, high $610.75) — a potential gain of +311% on today's $97.34. Momentum favours further upside here.
In 2050, INCY is projected to trade between $502.01 and $1,241.51, averaging $758.74 — a potential gain of +679% from today's $97.34. That is up +90% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in INCY today (≈ 10.273269 INCY) could be worth
$7,794.76
+$6,794.76 (+679%) by 2050 · US Dollar
Based on the average projected INCY price of $758.74 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in INCYwould be worth at today's price.
$1,000 invested in INCY on May 27, 2025 (≈ 15.302219 INCY) would be worth
$1,489.52
+$489.52 (+49.0%) today · 1.49× · US Dollar
Based on a INCY entry price of $65.35 vs. today's $97.34.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $97.08 | $1,002.68 | +0.3% |
| 1 month ago | $95.72 | $1,016.92 | +1.7% |
| 3 months ago | $100.09 | $972.52 | -2.7% |
| 6 months ago | $104.46 | $931.84 | -6.8% |
| 1 year ago | $65.35 | $1,489.52 | +49.0% |
| All time (5.0y) ago | $82.89 | $1,174.33 | +17.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our INCY forecast.
Our base-case forecast reaches $190.00 around 2032.
Implied market cap at $190.00: $37.96B
The multi-year forecast shows a clear path of upside into the next decade and beyond. The 2026 forecast sets the stage with an average of $97.16, rising through 2027 to $115.58 and then to $124.17 in 2028, $139.79 in 2029, and $148.61 in 2030. By 2031 the average reaches $182.36, followed by $214.53 in 2032 and $220.91 in 2033, then $248.48 in 2034 and $261.15 in 2035.
In 2040, the forecast shows an average of $410.82 and a max of $627.36, with the trajectory continuing into 2050 at an average of $780.53 and a max of $1,277.27. The forecast also maps rising ROI: 0% in 2026, 53% in 2030, 322.8% in 2040, and 703.3% in 2050, with sentiment turning bullish from 2028 onward.
These are estimates, not guarantees, and carry inherent uncertainty. Investors should consider the full range of outcomes and the potential for volatility over the horizon.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $148.61, with a low of $115.88 and a high of $203.03; ROI is 53% and sentiment is BULLISH.
The forecast indicates upside through the horizon, with average prices rising from $97.16 in 2026 to higher levels and a max of $1,277.27 by 2050; ROI reaches 703.3% by 2050, though these are estimates and not guarantees.
Yes. The 2030 maximum forecast is $203.03, and the 2032 maximum is $301.84, indicating the stock can exceed $200 under the forecast.
2035 average price is $261.15, with a minimum of $193.18 and a maximum of $380.67; ROI is 168.8% and sentiment is BULLISH.
2050 minimum is $516.38, average $780.53, maximum $1,277.27; ROI is 703.3% and sentiment is BULLISH.
Incyte Corporation Community Discussion
0Share your Incyte Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.